High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$19.9M
$19,895,148
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Bhatt Padmanabh P.
• Officer • Sr. VP of IP, CSO
10b5-1 Sell
2026-03-18
$359,621x2
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • Sr. VP of IP, CSO
10b5-1 Sell
|
2026-03-18 | $359,621x2 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Bhatt Padmanabh P.
• Officer • Sr. VP of IP, CSO
10b5-1 SellΔOwn -41.3%
2026-03-17
$2,514,886Largex2
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • Sr. VP of IP, CSO
10b5-1 SellΔOwn -41.3%
|
2026-03-17 | $2,514,886Largex2 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Bhatt Padmanabh P.
• Officer • Sr. VP of IP, CSO
10b5-1 SellΔOwn -48.2%
2026-03-16
$2,513,925Largex2
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • Sr. VP of IP, CSO
10b5-1 SellΔOwn -48.2%
|
2026-03-16 | $2,513,925Largex2 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Khattar Jack A.
• CEO
10b5-1 Sell
2026-03-13
$1,763,124Largex3
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2026-03-13 | $1,763,124Largex3 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Hudson Frederick M.
• Director
Discretionary Sell
2026-03-12
$271,725
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Discretionary Sell
|
2026-03-12 | $271,725 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Horich William Todd
• Officer • SVP, Commercial Operations
Discretionary Sell
2026-03-10
$244,145
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Commercial Operations
Discretionary Sell
|
2026-03-10 | $244,145 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Horich William Todd
• Officer • SVP, Commercial Operations
Discretionary SellΔOwn -50.0%
2026-03-09
$239,652
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Commercial Operations
Discretionary SellΔOwn -50.0%
|
2026-03-09 | $239,652 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Discretionary Sell
2026-03-09
$87,074
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Discretionary Sell
|
2026-03-09 | $87,074 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
GEMAYEL GEORGES
• Director
Discretionary SellΔOwn -24.4%
2026-03-06
$465,711
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Discretionary SellΔOwn -24.4%
|
2026-03-06 | $465,711 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
GEMAYEL GEORGES
• Director
Discretionary SellΔOwn -26.2%
2026-03-05
$537,100
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
Discretionary SellΔOwn -26.2%
|
2026-03-05 | $537,100 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Sensenig Bethany
• Director
10b5-1 SellΔOwn -27.2%
2026-02-19
$228,265x2
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
10b5-1 SellΔOwn -27.2%
|
2026-02-19 | $228,265x2 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
10b5-1 SellΔOwn -24.4%
2025-12-19
$1,008,150Largex2
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
10b5-1 SellΔOwn -24.4%
|
2025-12-19 | $1,008,150Largex2 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Bhatt Padmanabh P.
• Officer • Sr. VP of IP, CSO
Sell to Cover
2025-12-18
$31,552
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • Sr. VP of IP, CSO
Sell to Cover
|
2025-12-18 | $31,552 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Khattar Jack A.
• CEO
10b5-1 Sell
2025-10-09
$3,029,336Largex2
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-09 | $3,029,336Largex2 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
NEWHALL CHARLES W III
• Director
10b5-1 Sell
2025-10-09
$1,269,234Largex2
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2025-10-09 | $1,269,234Largex2 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-02 | $91,506 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-10-01 | $1,931,116Large | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-30 | $414,371 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-29 | $491,485 | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-23 | $1,393,899Large | S | Form 4 |
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
CEO
10b5-1 Sell
|
2025-09-22 | $779,921 | S | Form 4 |
|
SUPN
S
SUPERNUS PHARMACEUTICALS, INC.
Mottola Frank
• Officer • SVP, Chief Tech. Ops. Officer
Discretionary SellΔOwn -24.4%
2025-09-12
$229,350
|
||||||
| SUPN |
SUPERNUS PHARMACEUTICALS, INC.
|
Officer • SVP, Chief Tech. Ops. Officer
Discretionary SellΔOwn -24.4%
|
2025-09-12 | $229,350 | S | Form 4 |